Patient characteristics (N = 122) by MRD status
| Characteristic, n (%) . | MRD− . | MRD+ . | P . |
|---|---|---|---|
| No. of patients | 67 (55) | 55 (45) | |
| Age, y | |||
| < 10 | 30 (45) | 24 (44) | .90 |
| > 10 | 37 (55) | 31 (56) | |
| Sex | |||
| Male | 38 (57) | 39 (71) | .11 |
| Female | 29 (43) | 16 (29) | |
| Race | |||
| White | 50 (75) | 38 (69) | .50 |
| Nonwhite | 17 (25) | 17 (31) | |
| Disease | |||
| AML | 33 (49) | 25 (45) | .68 |
| ALL | 34 (51) | 30 (55) | |
| Disease status | |||
| CR1 | 52 (77) | 30 (55) | .001 |
| CR2 | 10 (15) | 13 (24) | |
| CR3 | 5 (7) | 1 (2) | |
| No remission | 0 (0) | 11 (20) | |
| Treatment era | |||
| Early cohort | 20 (30) | 25 (45) | .08 |
| Recent cohort | 47 (70) | 30 (55) | |
| Conditioning | |||
| TBI-based | 54 (81) | 48 (87) | .32 |
| Non-TBI | 13 (19) | 7 (13) | |
| Donor | |||
| Sibling | 20 (30) | 15 (27) | .92 |
| Unrelated | 33 (49) | 27 (49) | |
| Haploidentical | 14 (21) | 13 (24) | |
| T-cell depletion | |||
| Yes | 24 (36) | 26 (47) | .20 |
| No | 43 (64) | 29 (53) | |
| CMV status | |||
| R+/D+ | 12 (18) | 15 (27) | .23 |
| R+/D− | 13 (19) | 15 (27) | |
| R−/D+ | 14 (21) | 11 (20) | |
| R−/D− | 28 (42) | 14 (25) | |
| Outcome | |||
| Alive | 48 (72) | 22 (40) | .0001 |
| Died of leukemia | 4 (6) | 16 (29) | |
| Died of TRM | 15 (22) | 17 (31) | |
| Characteristic, n (%) . | MRD− . | MRD+ . | P . |
|---|---|---|---|
| No. of patients | 67 (55) | 55 (45) | |
| Age, y | |||
| < 10 | 30 (45) | 24 (44) | .90 |
| > 10 | 37 (55) | 31 (56) | |
| Sex | |||
| Male | 38 (57) | 39 (71) | .11 |
| Female | 29 (43) | 16 (29) | |
| Race | |||
| White | 50 (75) | 38 (69) | .50 |
| Nonwhite | 17 (25) | 17 (31) | |
| Disease | |||
| AML | 33 (49) | 25 (45) | .68 |
| ALL | 34 (51) | 30 (55) | |
| Disease status | |||
| CR1 | 52 (77) | 30 (55) | .001 |
| CR2 | 10 (15) | 13 (24) | |
| CR3 | 5 (7) | 1 (2) | |
| No remission | 0 (0) | 11 (20) | |
| Treatment era | |||
| Early cohort | 20 (30) | 25 (45) | .08 |
| Recent cohort | 47 (70) | 30 (55) | |
| Conditioning | |||
| TBI-based | 54 (81) | 48 (87) | .32 |
| Non-TBI | 13 (19) | 7 (13) | |
| Donor | |||
| Sibling | 20 (30) | 15 (27) | .92 |
| Unrelated | 33 (49) | 27 (49) | |
| Haploidentical | 14 (21) | 13 (24) | |
| T-cell depletion | |||
| Yes | 24 (36) | 26 (47) | .20 |
| No | 43 (64) | 29 (53) | |
| CMV status | |||
| R+/D+ | 12 (18) | 15 (27) | .23 |
| R+/D− | 13 (19) | 15 (27) | |
| R−/D+ | 14 (21) | 11 (20) | |
| R−/D− | 28 (42) | 14 (25) | |
| Outcome | |||
| Alive | 48 (72) | 22 (40) | .0001 |
| Died of leukemia | 4 (6) | 16 (29) | |
| Died of TRM | 15 (22) | 17 (31) | |
CR indicates complete remission; early cohort, AML97 and Total Therapy 13/14; recent cohort, AML02 and Total Therapy 15; TBI, total body irradiation; R, recipient; and D, donor.